- Home /
- Research /
- Programs /
- Respiratory Diseases /
- CanCOLD
CanCOLD – Canadian Cohort Obstructive Lung Disease
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, according to the World Health Organization. In Canada, despite low awareness in the public and medical community, COPD is also the main cause of hospital admission for chronic illness. With aging populations, the global prevalence of COPD is rapidly growing. Beyond its impacts on the quality of life of patients and their families, COPD is an extremely costly disease. The Conference Board of Canada has estimated that the yearly costs of the disease will increase from $4 billion in 2010 to $9.5 billion by 2030.
CanCOLD is a collaborative Canada-wide study advancing knowledge of why people develop COPD, how and why COPD impacts individuals differently, and how to provide better care for people affected by this disease
Hosted at the RI-MUHC, the Canadian Cohort Obstructive Lung Disease (CanCOLD) study is a longitudinal study following approximately 1,500 participants in Canada since 2009. CanCOLD aims to enhance the current understanding of COPD progression and burden, and to better advance COPD prevention, diagnosis and management. Public and private investments of more than $14 million have allowed the CanCOLD study to produce policy-relevant knowledge and innovative solutions that have a positive impact on public health and clinical practice. CanCOLD leverages partnerships between researchers and organisations, providing opportunities for graduate students to be trained and young investigators to participate in innovative respiratory health research projects in many institutions across Canada.
- Objectives
- Study overview
- A resource for the research community
- Additional information
- Research project team
- Contact information
Objectives
- identifying combinations of disease and patient attributes that differentiate individuals with COPD, and studying the relationship of these attributes to relevant outcomes;
- evaluating past and current clinical practice for the care of mild and moderate COPD.
Study overview
During each assessment, the CanCOLD study collects a deep pool of information that can be queried to address research questions related to COPD. This information includes standardized questionnaires on lifestyles and behaviours, health status, quality of life, psychological health, occupational health, sleep quality and socio-demographics. Respiratory health is additionally evaluated by telephone contact every 3 months, when participants respond to a COPD exacerbation questionnaire, with questions on symptom changes, medication and health service use. Through in-site assessments, CanCOLD has also collected physical measurements such as pulmonary function tests, cardiopulmonary exercise tests (CPET), CT scans of participants’ chest and lungs, and biospecimens. The CanCOLD cohort data is further enriched by the information available in linked external databases. These databases include administrative health data, such as physician billing claims and hospitalizations, and environmental exposure data, such as ambient air pollution exposure and climate and weather events data distributed by the Canadian Urban Environmental Health Research Consortium (CANUE).
The CanCOLD study protocol, including study description, design, measurements and participant eligibility criteria, is published on the National Institutes of Health ClinicalTrials.org public registry website.
A resource for the research community
Additional information
For additional information on CanCOLD, including how to access the CanCOLD data for a research project, please contact us or visit our website at: www.cancold.ca
To support the CanCOLD study, please visit the McGill University Health Centre Foundation fundraising page.
Research project team
Contact information
For more information about CanCOLD, email dany.dorion [at] affiliate.mcgill.ca.
Jean Bourbeau, MD, M.Sc., FRCPC
Co-Principal Investigator and Principal Investigator, Montreal site
Dr. Bourbeau is a senior scientist in the Translational Research in Respiratory Diseases Program at the Research Institute of the MUHC.
Wan-Cheng Tan, MD, FRCP (Lon), FCCP
Co-Principal Investigator and Principal Investigator, Vancouver site
Dr. Tan is Professor in the Department of Medicine, UBC, and the Division of Respiratory Medicine, St. Paul’s Hospital, Vancouver.